ma cosa cavolo scrivono??
valutazione 199 milioni dollari australiani???
al cambio 160 milioni di dollari americani circa...!!
cioe' 3 dollari e 20 centesimi ad azione..!!
Roba da denu...ncia....
Prima BioMed (PRR)
Business description
Prima BioMed has a pipeline of four immunotherapy candidates; lead products include IMP321, a post-chemotherapy stimulant and CVac, an autologous dendritic cell immune therapy in development for ovarian cancer patients in remission.
Share price chart
Share chart
LAG-3 comes to the fore
Outlook | Pharmaceutical & Healthcare | 14/04/2015
Next
Previous
Prima BioMed has switched its focus from CVac to IMP321 since acquiring the French immunotherapy company Immutep for A$26m. A Phase II study in metastatic breast cancer with IMP321 is due to start in H215; the product has potential across many tumours, with other immunotherapies and chemotherapy. CVac still has potential in ovarian cancer and other epithelial tumours, and Prima is looking for a partner to develop it further. Prima's two other assets gained with Immutep are partnered with GSK and Novartis. Our valuation is A$199m vs A$101m before the acquisition.